Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5905] to AACT - BSA and Azide free
- Suitable for: IP, WB
- Reacts with: Human
Product nameAnti-AACT antibody [EPR5905] - BSA and Azide free
See all AACT primary antibodies
DescriptionRabbit monoclonal [EPR5905] to AACT - BSA and Azide free
Tested applicationsSuitable for: IP, WBmore details
Species reactivityReacts with: Human
Synthetic peptide within Human AACT aa 250-450. The exact sequence is proprietary.
- WB: Human plasma; Human colon cancer lysate.
Ab232054 is the carrier-free version of ab129194. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
ab232054 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab232054 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Detects a band of approximately 68 kDa (predicted molecular weight: 47 kDa).|
FunctionAlthough its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.
Tissue specificityPlasma. Synthesized in the liver. Like the related alpha-1-antitrypsin, its concentration increases in the acute phase of inflammation or infection. Found in the amyloid plaques from the hippocampus of Alzheimer disease brains.
Involvement in diseaseDefects in SERPINA3 may be a cause of chronic obstructive pulmonary disease (COPD) [MIM:107280].
Sequence similaritiesBelongs to the serpin family.
DomainThe reactive center loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site within the RCL, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.
- Information by UniProt
- SERPINA3 antibody
- AACT antibody
- AACT_HUMAN antibody
All lanes : Anti-AACT antibody [EPR5905] (ab129194) at 1/10000 dilution
Lane 1 : Human plasma lysate
Lane 2 : Human colon cancer lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 47 kDa
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab129194).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab232054 has not yet been referenced specifically in any publications.